https://www.selleckchem.com/
gy. The Food and Drug Administration recently approved two percutaneous arteriovenous fistula creation systems the Ellipsys vascular access (EL) system and WavelinQ EndoAVF (WQ) system. Although the initial clinical trials of each system have demonstrated a high success rate, little detail on anatomic suitability was provided. We sought to determine the real-world applicability of the EL and WQ systems by studying them in a single representative cohort. All patients receiving a first-time arteriovenous access consultation at a single Veterans Affairs instit
Like
Comment
Share
